Dorsey & Whitney Trust CO LLC Purchases Shares of 15,796 Organon & Co. (NYSE:OGN)

Dorsey & Whitney Trust CO LLC purchased a new stake in Organon & Co. (NYSE:OGN) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 15,796 shares of the company’s stock, valued at approximately $236,000.

Several other large investors have also recently bought and sold shares of OGN. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. during the third quarter worth approximately $25,000. Horizon Bancorp Inc. IN increased its holdings in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the period. Larson Financial Group LLC increased its holdings in shares of Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares during the period. Riverview Trust Co increased its holdings in shares of Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the period. 77.43% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Morgan Stanley decreased their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $15.69 on Wednesday. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a market capitalization of $4.05 billion, a P/E ratio of 4.71, a P/E/G ratio of 0.90 and a beta of 0.76. The company’s 50 day moving average price is $15.46 and its two-hundred day moving average price is $16.80.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, equities analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be issued a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.14%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.